Covalent binding to glutathione of the DNA-alkylating antitumor agent, S23906-1 Marie-He´le`ne David-Cordonnier1, William Laine1, Alexandra Joubert1, Christelle Tardy1, Jean-Franc¸ois Go
Trang 1Covalent binding to glutathione of the DNA-alkylating antitumor agent, S23906-1
Marie-He´le`ne David-Cordonnier1, William Laine1, Alexandra Joubert1, Christelle Tardy1,
Jean-Franc¸ois Goossens2, Mostafa Kouach3, Gilbert Briand3, Huong Doan Thi Mai4, Sylvie Michel4, Francois Tillequin4, Michel Koch4, Ste´phane Leonce5, Alain Pierre5and Christian Bailly1
1
INSERM U-524 et Laboratoire de Pharmacologie Antitumorale du Centre Oscar Lambret, IRCL, Lille, France;2Laboratoire de Chimie Analytique, Faculte´ desSciencesPharmaceutiqueset Biologiques, et3Laboratoire de Spectrome´trie de Masse,
Universite´ de Lille, Lille, France;4Laboratoire de Pharmacognosie, Universite´ Rene´ Descartes (Paris 5), CNRS UMR8638, Faculte´ des Sciences Pharmaceutiques et Biologiques, Paris, France;5Division Recherche Cance´rologie,
Institut de Recherches SERVIER, Croissy sur Seine, France
The benzoacronycine derivative, S23906-1, was
character-ized recently as a novel potent antitumor agent through
alkylation of the N2 position of guanines in DNA We show
here that its reactivity towards DNA can be modulated
by glutathione (GSH) The formation of covalent adducts
between GSH and S23906-1 was evidenced by EI-MS, and
the use of different GSH derivatives, amino acids and
dipeptides revealed that the cysteine thiol group is absolutely
required for complex formation because glutathione
disul-fide (GSSG) and other S-blocked derivatives failed to react
covalently with S23906-1 Gel shift assays and fluorescence
measurements indicated that the binding of S23906-1 to
DNA and to GSH are mutually exclusive Binding of
S23906-1 to an excess of GSH prevents DNA alkylation
Additional EI-MS measurements performed with the mixed
diester, S28053-1, showed that the acetate leaving group at
the C1 position is the main reactive site in the drug: a reaction
scheme common to GSH and guanines is presented At the
cellular level, the presence of GSH slightly reduces the cytotoxic potential of S23906-1 towards KB-3-1 epidermoid carcinoma cells The GSH-induced threefold reduction of the cytotoxicity of S23906-1 is attributed to the reduced formation of lethal drug–DNA covalent complexes in cells Treatment of the cells with buthionine sulfoximine, an inhibitor of GSH biosynthesis, facilitates the formation of drug–DNA adducts and promotes the cytotoxic activity This study identifies GSH as a reactant for the antitumor drug, S23906-1, and illustrates a pathway by which GSH may modulate the cellular sensitivity to this DNA alkylating agent The results presented here, using GSH as a biological nucleophile, fully support our initial hypothesis that DNA alkylation is the major mechanism of action of the promising anticancer drug S23906-1
Keywords: glutathione; DNA alkylation; acronycine; anti-cancer drug; mechanism of action
Introduction
The alkaloid acronycine (Fig 1) was first isolated fromthe
bark of Acronychia baueri (also known as
Sarcomeli-cope simplicifolia), a Rutaceous tree widely distributed in
Australia [1,2] This tetracyclic alkaloid was shown to be moderately cytotoxic to a wide range of tumor cells in vitro [3,4] and to display antitumor activities in vivo [5] However, clinical testing of acronycine itself showed a poor response and the development of this compound was arrested in the early 1980s Nevertheless, the antitumor potential of acronycine has stimulated the synthesis of numerous analogues [6–8] Recently, the benzoacronycine derivative, S23906-1 (Fig 1), was identified as a potent anticancer drug with activity against a variety of human tumor xenograft models in mice [9,10] S23906-1 has been selected for advanced preclinical evaluation
Froma mechanistic point of view, S23906-1 was recently characterized as a DNA alkylating agent reacting irrevers-ibly with guanine residues at the N2 position in double-stranded DNA [11] The covalent binding to DNA is apparently responsible for the cytotoxic action [12] and the capacity of the drug to trigger apoptosis in tumor cells [13,14] In the course of our ongoing studies aimed at characterizing the interaction of S23906-1 with biologically significant molecules, the reaction with glutathione (GSH) was examined The observation that a tricyclic analogue
of S23906-1 (i.e 1,2-dihydroxy-1,2-dihydroacronycine diacetate) reacts covalently with benzyl mercaptan to form
Correspondence to C Bailly, INSERM U-524 et Laboratoire de
Pharmacologie Antitumorale du Centre Oscar Lambret, IRCL,
59045 Lille, France.
Fax: + 33 320 16 92 29, Tel.: + 33 320 16 92 18,
E-mail: bailly@lille.inserm.fr
Abbreviations: BSO, buthionine sulfoximine; CD, circular dichroı¨sm;
Cys, L -cysteine; Cys-Gly, cysteine-glycine; EI-MS, electrospray
ion-ization mass spectroscopy; c-Glu-Cys, gamma-glutamic acid-cysteine;
Gln, L -glutamine; c-Glu-Gly, gamma-glutamic acid-glycine;
GS-DCE, S-dicarboxyethyl-glutathione; GS-Me,
S-methyl-glutathi-one; GS-NO, S-nitrosoglutathiS-methyl-glutathi-one; GS-SA, glutathione sulfonic acid;
GSH-O-Et, glutathione reduced ethyl ester; GSSG, oxidized
gluta-thione; IC 50 , 50% inhibitory concentration; MC, mitomycin C;
Met, L -methionine; N-Ac-Cys, N-acetyl- L -cysteine.
(Received 10 March 2003, revised 05 May 2003,
accepted 12 May 2003)
Trang 2an S-linked adduct prompted us to initiate this work [6].
GSH, which is an abundant intracellular tripeptide (L
-c-glutamyl-L-cysteinyl-glycine), was used as a model
bio-nucleophile to investigate further the reactivity of S23906-1
Direct experimental evidences for the formation of covalent
adducts between S23906-1 and GSH are reported here, and
a reaction scheme common to DNA and GSH is described
Materials and methods
Chemicals and biochemicals
Synthesis of the benzoacronycine derivatives has been
reported previously [7] The enantiomers S27589-1 and
S27590-1 were obtained fromthe racemate S23906-1 by
HPLC on a cellulose stationary phase (Chiralcel OC; Chiral
Technologies, Strasbourg, France) Synthesis of S28053-1
will be reported elsewhere, together with that of related
mixed esters and diacid hemiesters Reduced glutathione
(GSH) and oxidized glutathione (GSSG), as well asL
-cys-teine (Cys), N-acetyl-L-cysteine (N-Ac-Cys), L-methionine
(Met), L-glutamine (Gln), gamma-glutamic acid-cysteine
(c-Glu-Cys), cysteine-glycine (Cys-Gly), gamma-glutamic
acid-glycine (c-Glu-Gly), S-methyl-glutathione (GS-Me),
S-nitrosoglutathione (GS-NO),
S-dicarboxyethyl-glutathi-one (GS-DCE), glutathiS-dicarboxyethyl-glutathi-one reduced ethyl ester
(GSH-O-Et), glutathione sulfonic acid (GS-SA) and buthionine
sulfoximine (BSO) were purchased from Sigma Aldrich
DNA restriction fragments
The pBS plasmid was digested with PvuII and EcoRI and
the resulting 117-bp fragment was labeled at the EcoRI site
with [a-32P]dATP and avian myeloblastosis virus (AMV)
reverse transcriptase Electrophoresis on a nondenaturing
6% (w/v) polyacrylamide gel served to remove excess
radioactive nucleotide, with the desired 3¢ end-labeled
product being cut out of the gel and eluted overnight in
500 mMammonium acetate/10 mMmagnesium acetate and
then ethanol precipitated
Gel-shift studies
A typical cross-linking reaction consisted of incubating
10 lL of radiolabeled DNA, 2 lL of buffer (10 m Na
cacodylate, pH 7.0; Tris buffer was avoided owing to the presence of reactive amine functions) and 10 lL of the drug
at the desired concentration in the dark at roomtempera-ture, during the period specified in the legend, prior to adding 5 lL of a 50% glycerol solution containing tracking dyes To study the inhibition of DNA alkylation, S23906-1 (50 lM) was first incubated with an excess of GSH or derivatives (400 lM) in 20 lL of ammonium acetate for 1 h
at 37C prior to the addition of the radiolabeled DNA for a further 2-h incubation period at 37C DNA samples were resolved by electrophoresis under nondenaturing conditions
in 6% acrylamide gels for 5 h at 300 V at room temperature in TBE buffer (89 mMTris base/89 mMboric acid/2.5-mMNa2EDTA, pH 8.3) Gels were transferred to Whatman 3MM paper, dried under vacuum at 80C, and then analyzed on a phosphorimager (Molecular Dynamics 445SI)
Circular dichro (CD) The CD spectra were obtained using a J-810 Jasco spectropolarimeter at 20C controlled by a PTC-424S/L Peltier type cell changer (Jasco Inc., Easton MD, USA) A quartz cell of 10-mm path length was used to obtain spectra from450 to 290 nmwith a resolution of 0.1 nm The drug, S27590-1 (50 lM final concentration), was incubated in
1 m L of 1 mM ammonium acetate, pH 7.15, with or without (control) 1 mM GSH, GSSG, Cys, N-Ac-Cys, Cys-Gly, GS-Me or GS-NO (froma 100-mMstock solution previously equilibrated at pH 8.0 using KOH) in 1 mM ammonium acetate CD spectra were collected every 10 min from0 to 150 min
Electrospray ionization mass spectroscopy (EI-MS) The spontaneous hydrolysis of S28053-1 was monitored by EI-MS using a drug solution of 250 lMin 200 lL of 1 mM ammonium acetate, pH 8.0, and analyzing the sample at the various time-points specified in the figure legend For the alkylation reactions, the various GSH derivatives (100 lM) were incubated for 16 h at 20C, either alone or with
100 lM S23906-1, S27589-1, S27590-1 or S28053-1 in
200 lL of 1 mMammonium acetate, pH 8.0 Samples were injected in a simple-quadruple MS API I (Perkin-Elmer Sciex) equipped with an ion-spray (nebulizer-assisted elec-trospray) source (Sciex, Toronto, Canada) using a needle prewashed with methanol The solutions were infused continuously with a medical infusion pump (Model 11, Harvard Apparatus, South Natick, USA) at a flow rate of
5 lLÆmin)1 Polypropylene glycol was used to calibrate the quadrupole Ion spray mass spectra were acquired at unit resolution by scanning from m/z 200–800 with a step size of 0.1 Da and a dwell time of 2 ms Twenty spectra were summed and recorded at an orifice voltage of +50 V, whereas the potential of the spray needle was held at +5 kV
Alkylation of plasmids and fluorescence measurements Compound S23906-1 (100 lM) was incubated with or without increasing amounts of GSH or GSSG pre-equilibrated at pH 8.0 from100 l to 25 m in 200 lL
Fig 1 Structure of the racemic cis diacetate compound, S23906-1 and
the mixed ester analogue, S28053-1 Compounds S27590-1 and
S27589-1 correspond to the individual enantiomeric R,R and S,S forms of the
racemate S23906-1, obtained by chiral HPLC.
Trang 3of incubation buffer (1 mMammonium acetate) for 6 h at
roomtemperature prior to adding 10 lg of the plasmid and
a further 16 h of incubation at 37C Free drug molecules
were separated fromDNA cross-linked molecules by
phenol/chloroform/isoamyl alcohol (25 : 24 : 1) extraction
followed by addition of 5 lL of 5-MNaCl and precipitation
of DNA using 1 mL of cold ethanol After centrifugation at
13 800 g for 30 min, the DNA pellet was dried and
dissolved in 1 mL of incubation buffer The fluorescence
of the compound covalently linked to DNA was measured
using an excitation wavelength of 354 nmand an emission
range from420 to 650 nm Spectra were recorded using a
SPEX spectrofluorimeter Fluorolog
Cell culture
KB-3-1 epidermoid carcinoma cells [15] were grown in
DMEM (Dulbecco’s modified Eagle’s medium)-glutaMAX
medium (Gibco) supplemented with 10% fetal bovine
serum, penicillin (100 IUÆmL)1) and streptomycin (100Æ
lg/mL) in a humidified atmosphere at 37C under 5%
CO2 The cells were harvested by trypsinization and plated
24 h before treatment with the test drug
Survival assay
The cytotoxicity of S23906-1 and the effects of GSH or
derivatives on the cytotoxicity of this compound were
assessed using a cell proliferation assay developed by
Promega (CellTiter 96AQueousone solution cell
prolifer-ation assay) Briefly, 3· 103exponentially growing KB-3-1
cells were seeded in 96-well microculture plates for 24 h
prior to treatment with graded concentrations of S23906-1
and 1-mMGSH or derivatives, in six independent points
After 72 h of incubation at 37C, 20 lL of the tetrazolium
dye was added to each well and the samples were incubated
for a further 2 h at 37C Plates were analyzed on a
Labsystems Multiskan MS (type 352) reader at 492 nm
Detection of S23906-1-DNA adducts in KB-3-1 cells
in the presence of GSH
Approximately 1.5· 106KB-3-1 cells were grown for 24 h
in 100-mm diameter dishes with 5 mL of culture medium,
prior to the addition of GSH or derivatives (1 mM each)
and S23906-1 (10 lM) for 24 h The genomic DNA was
extracted fromcells as described previously [11] Briefly,
after the drug treatment, cells were collected by
centrifuga-tion (5 min, 188 g), washed twice with 10 mL of NaCl/Pi
buffer and resuspended in 2 mL of NaCl/Pi containing
5 mMMgCl2prior to the addition of 200 lL of 10% SDS
and mild agitation for 5 min Proteinase K (80 lL of a
10-mgÆmL)1stock solution) was added for a further 5 min
of mild agitation, and finally 200 lL of 0.1M EDTA,
pH 7.5, was added and the mixture incubated for 4 h at
37C After addition of 80 lL of 5MNaCl, the DNA was
extracted using 3 mL of phenol/chloroform/isoamyl alcohol
(25 : 24 : 1) and centrifuged at 3000 g for 10 min, followed
by two extractions with 3 mL of chloroform/isoamyl
alcohol (24 : 1) Finally, the DNA was precipitated with
cold ethanol and collected by centrifugation at 19 000 g for
30 min The pellet was then dissolved in 200 lL of HO and
treated for 2 h with 5 lMRNase A (10 mgÆmL)1) to avoid RNA contamination The DNA concentration was estimated by spectrophotometry at 260 nm The fluores-cence of S23906-1 covalently linked to DNA was measured using a SPEX Fluorolog spectrofluorimeter with an excitation wavelength at 300 nmand an emission range from 420 to 555 nm A similar procedure was used to detect S23906-1–DNA adducts in KB-3-1 cells previously treated using BSO KB-3-1 cells, prepared as described above, were treated for 24 h with increasing concentrations
of BSO prior to treatment with S23906-1 Genomic DNA was extracted and the fluorescence quantified as described above
Determination of the intracellular GSH content KB-3-1 cells (1· 106 cells/dish) were incubated in the presence or absence of BSO for 24 h, as described above Cells were then collected, washed with 10 mL of NaCl/Pi and resuspended in 200 lL of NaCl/Pi prior to lysis by freezing and thawing twice The ThioGlo-1TM(Calbiochem) reagent (10 lM) was then added to the lysate (froma fresh 10-mMstock solution in dimethylsulfoxide) and the fluor-escence was immediately measured with an excitation wavelength of 360 nmand an emission wavelength of 400–650 nm
Results
Molecular studies Two complementary techniques, EI-MS and CD, were deployed to study the reaction of the benzoacronycine derivative, S23906-1, with GSH MS is particularly well suited for detecting the covalent adducts formed between S23906-1 and the tripeptide This is shown in the mass spectrumgiven in Fig 2A, with well-resolved peaks at
MH+¼ 308, 406, 448 and 490 corresponding to GSH and
to the diol, mono-acetate and di-acetate forms of the parent drug, respectively The latter three species reflect the hydrolysis of the compound in solution (see the results below with the analogue S28053-1) In addition, the incubation of S23906-1 with GSH for 16 h in 1-mM ammonium acetate yielded two species with a mass of
MH+¼ 695 and 737 They corresponded to the expected mass for the covalent GSH-drug adducts, with either one remaining acetate (MH+¼ 737) or an OH group (MH+¼ 695), at the C2 position Direct evidence is given below for a reaction with GSH implicating the C1 position These two peaks at MH+¼ 737 and 695 provide strong evidence that the drug forms covalent complexes with the tripeptide
Similar MS experiments were performed after reacting S23906-1 with various GSH analogues differently substi-tuted or with amino acids and dipeptides each representing
a portion of the L-c-glutamyl-L-cysteinyl-glycine parent compound Typical mass spectra obtained with Cys, N-acetyl-Cys, c-Glu-Cys, Cys-Gly and GSH-O-Et are presented in Figs 2B–2F, respectively In all cases with the compounds bearing a free SH group, we were able to detect the formation of covalent adducts with S23906-1 The reaction is particularly strong with Cys because, in this case,
Trang 4the Cys–drug adducts are detected readily (either the
mono-acetate form at MH+¼ 551 or the OH format
MH+¼ 509), with very little drug remaining unbound
(species at MH+¼ 406 (diol) or 448 (monoacetate) The
reaction is also very pronounced with the dipeptide Cys-Gly
(Fig 2E), whereas the level of adducts is much smaller (but
still observed) with the c-Glu-Cys dipeptide (Fig 2D) This
suggests that the drug preferentially recognizes the Gly side
of the tripeptide
In contrast, absolutely no covalent adducts were detected
with other GSH-related compounds lacking the free thiol
group The compounds tested are listed in Table 1 The list
includes the oxidized formGSSG and the S-protected GSH
derivatives GS-Me, GS-NO, GS-DCE and GS-SA, but also
smaller compounds such as Met, Gln and c-Glu-Gly None
of these compounds was able to react covalently with
S23906-1, indicating that the SH group is strictly required
for the formation of covalent adduct with the
benzoacro-nycine derivative
The second method used to provide evidence for the formation of complexes between S23906-1 and GSH is CD Because this spectroscopic approach requires optically active molecules, we did not use S23906-1 itself but the pure enantiomeric forms S27590-1 and S27589-1, which are the two cis enantiomers with the acetate groups located either above or below the plane of the aromatic chromo-phore (Fig 1) These two compounds are equitoxic toward different tumor cell lines (data not shown) and also react equally well with DNA This is shown in Fig 3 fromthe gel-shift experiments performed with a 117-bp radiolabeled DNA substrate incubated with graded concentrations of S27589-1 or S27590-1 for 2 h (Fig 3A) or with a single dose
of each compound for up to 2 h (Fig 3B) The band of DNA showing a retarded electrophoretic mobility reflects the formation of covalent adducts, as recently described [11] It is clear fromthese kinetic experiments that the two cisenantiomers present equal capacities to react covalently with DNA
The reaction of compounds S27589-1 and S27590-1 with GSH was then monitored by CD As shown in Fig 4A, the
CD spectrumof S27590-1 is altered upon reaction with GSH, but no change occurs with GSSG Monitoring the changes of the CD signal at 300 nmallows us to distinguish the SH and S-protected compounds With the former, such
as GSH, Cys and Cys-Gly (open symbols in Fig 4B), the
CD amplitude at 300 nm largely decreases With the latter, including GS-Me and GS-NO, for example (filled symbols
in Fig 4B), variations of the CD sign are extremely limited This method thus provides an easy way to distinguish reactive (free SH) vs nonreactive (S-protected) species Although this technique cannot distinguish between binding and bonding, the data nicely complement the MS results to support the formation of stable complexes between GSH and the benzoacronycine derivatives
We have previously demonstrated that S23906-1 reacts covalently with DNA [11] and we now show that it also forms stable adducts with GSH Two potential targets have thus been identified Competition experiments were per-formed to determine whether the bonding to GSH can prevent DNA alkylation For this purpose, the drug was first incubated for 1 h with an excess of GSH or related compounds containing a free SH group (such as GSH-O-Et, the dipeptide Cys-Gly or the amino acid Cys) or an S-protected function (such as GSSG or GS-NO) prior to addition of the 117-bp radiolabeled DNA fragment After a 2-h reaction at 37C, the DNA samples were analyzed by electrophoresis on polyacrylamide gels The results are displayed in Fig 5 The alkylation of DNA is visualized by
an important gel shift and the degree of retardation depends
on the capacity of the drug to react with the competing GSH-related product GSH binding to native DNA and to alkylated DNA was insignificant Preincubation of
S23906-1 with Cys totally prevented the formation of DNA–drug adducts An incomplete inhibition of DNA–S23906-1 complex formation was also observed with GSH and the SH-containing compounds GSH-O-Et, Cys-Gly and, to a lesser extent, c-Glu-Cys and N-Ac-Cys It is important to note that despite the large excess of GSH compared with the drug (400-lMGSH vs 50-lM S23906-1), the reactivity of the drug towards DNA was not completely abolished This can be important at the cellular level
Fig 2 EI-MS analysis of the alkylation of glutathione (GSH) and its
derivatives by S23906-1 S23906-1 (100 l M ) was incubated with 100 l M
GSH (M ¼ 307, panel A), L -cysteine (Cys) (M ¼ 121, panel B),
N-acetyl- L -cysteine (N-Ac-Cys) (M ¼ 163, panel C), gamma-glutamic
acid-cysteine (c-Glu-Cys) (M ¼ 250, panel D), cysteine-glycine
(Cys-Gly) (M ¼ 178, panel E) or glutathione reduced ethyl ester
(GSH-O-Et) (M ¼ 335, panel F) for 16 h at roomtemperature in 1 m M
ammonium acetate, pH 7.15, prior to performing MS measurements
in the positive ion mode Among the different species identified for
each spectrum, three species present the same molecular weight and
correspond to the uncomplexed molecules: (·) the diol form
(MH +
¼ 406) and (.) the mono-acetate form (MH +
¼ 448) derived fromspontaneous hydrolysis of (*) the parent di-acetate form
(MH+¼ 490) Covalent binding of the drug to GSH (MH +
¼ 308)
or its derivatives gives adducts where one () or two (fl) acetate groups
of S23906-1 are lost In panel B, the peak at MH +
¼ 241 corresponds
to [2xCys]H+ In panel G, peaks at MH+¼ 336 and 669 correspond
to GSH-O-Et and [2xGSH-O-Et]H + , respectively.
Trang 5Table 1 Summary data The + refers to SH-containing glutathione (GSH) derivatives which interact with S23906-1 to modify the spectrum of circular dichroı¨sm, form a covalent adduct identified by MS, compete with DNA in gel-shift assays, inhibit the alkylation of genomic DNA by S23906-1 and reduce the cytotoxicity of S23906-1 in the survival assay using KB-3-1 cell line The 0 refers to the S-protected GSH derivatives which neither interact with S23906-1 nor modulate its cellular activity +/–, Weak effect; ND, not determined Cys, L -cysteine; Cys-Gly, cysteine-glycine; c-Glu-Cys, gamma-glutamic acid-cysteine; Gln, L -glutamine; c-Glu-Gly, gamma-glutamic acid-glycine; GS-DCE, S-dicarboxyethyl-glutathione; GS-Me, S-methyl-glutathione; GS-NO, S-nitrosoglutathione; GS-SA, glutathione sulfonic acid; GSH-O-Et, glutathione reduced ethyl ester; GSSG, oxidized glutathione; Met, L -methionine; N-Ac-Cys, N-acetyl- L -cysteine.
Compound
Circular dichroı¨smMS
Gel-shift competition
Alkylation of genomic DNA
Survival assay
Fig 3 Concentration- and time-dependence for the alkylation of DNA
by S27589 and S27590 using electromobility shift assays (A) The drug
at the indicated micromolar concentration was incubated with a
117-bp radiolabeled DNA fragment for 2 h at room temperature prior to
PAGE on a nondenaturing 6% gel (B) The drug at a fixed
concen-tration of 50 l M was reacted with DNA for up to 120 min In both (A)
and (B), experiments were performed in 1 m M sodiumcacodylate,
pH 7.0, and the free and bound DNA forms were separated by PAGE
on nondenaturing 6% gels Control tracks labeled DNA contained
no drug; (b) and (f) refers to bound and free DNA, respectively.
Fig 4 Circular dichroı¨sm (CD) analysis of the interaction of glutathi-one (GSH) or its derivatives with the diacetate compound S27590 (A)
CD spectra of S27590 (50 l M ) incubated alone (thinner line), with 1 m M
GSH (broken line) or with 1 m M glutathione disulfide (GSSG) (thick line) for 90 min at 20 C In (B), the intensity of the CD band centered
at 300 nm, characteristic of the GSH–drug complexes, is plotted vs time S27590 (50 l M ) was incubated with 1-m M GSH (n), GSSG (m),
L -cysteine (Cys) (s), N-acetyl- L -cysteine (N-Ac-Cys) (e), cysteine-glycine (Cys-Gly) (h), S-methyl-glutathione (GS-Me) (d) or S-meth-ylglutathione (GS-NO) (j) in 1-m ammonium acetate, pH 7.15.
Trang 6In sharp contrast to that observed with GSH, no
inhibition of DNA alkylation was detected with the
S-protected compounds, in particular GSSG, NO,
GS-DCE or GS-SA This is again a strong indication that the
SH group of the tripeptide is required for covalent complex
formation with the benzoacronycine derivative The fact
that the inhibitory effect is significantly more pronounced
with dipeptide Cys-Gly than with c-Glu-Cys suggests that
the drug may establish contact with the Gly side of the
peptide to react with the adjacent SH group on the central
Cys residue, in agreement with the MS data presented
above These experiments indicate that the same reactive site
on the drug molecule is implicated in the covalent binding to
DNA and GSH The two targets compete for the same
electrophilic species
The competition between DNA and GSH was
investi-gated further by fluorescence spectroscopy The drug was
incubated for 6 h with GSH or GSSG prior to addition of
the DNA (in this case a supercoiled plasmid was used) and
the reaction was performed for 15 h at 37C Unbound
drug molecules were then extracted with phenol/chloroform
and the remaining DNA was precipitated with ethanol The
fluorescence spectrumof the DNA-bound S23906-1 species
was then recorded The results shown in Fig 6A clearly
reveal that the preincubation of the drug with GSSG had
no effect on the capacity of the drug to alkylate DNA,
whereas the incubation with GSH considerably reduced the
extent of drug–DNA covalent complex formation This is
also shown in the concentration-dependence plot in
Fig 6B A concentration of 1-mM GSH (i.e close to the
intracellular level) reduces, by about 40%, the capacity of
S23906-1 to bond to DNA At 10-mMGSH, the extent of
DNA alkylation by S23906-1 is reduced by 70%
Alto-gether, the gel-shift assays (Fig 5) and fluorescence data
(Fig 6) unambiguously reveal that the reaction of S23906-1
with GSH and DNA is mutually exclusive Bonding to the peptide target modulates binding to the nucleic acid and vice versa However, it should be noted that even a massive GSH concentration, such as 10 mM(exceeding the physio-logical concentration), does not completely abolish DNA alkylation
On the basis of structure–DNA alkylation and structure– activity relationships, we have recently shown that the reactive site on the S23906-1 molecule is the C1 position bearing a leaving acetate group [12] The same reactive site must be involved in the reaction with the thiol function of GSH To investigate this further, we performed a detailed
MS analysis with an analogue of S23906-1 bearing two different ester groups at the C1 and C2 positions The mixed diester S28053-1 (Fig 1) bears an acetate group at C1 and a hemisuccinate group at C2, enabling a facile distinction between the two ester groups by means of MS This compound, used here specifically to investigate the mech-anismof action of the parent compound, is as potent as S23906-1 at alkylating DNA (data not shown)
Figure 7 shows the hydrolysis data for a solution of S28053-1 incubated for up to 20 h in the ammonium acetate
Fig 6 Effects of glutathione (GSH) and glutathione disulfide (GSSG)
on DNA alkylation by S23906-1 (A) The fluorescence-emission spectra were recorded after incubation of S23906-1 with GSH or GSSG for
6 h at 37 C followed by the addition of plasmid DNA (10 lg) for a further 15-h incubation period at 37 C The DNA was then extracted, precipitated and resuspended in buffer for measurement of fluores-cence at an excitation wavelength of 354 nm S23906-1 (100 l M ) alone (plain line), or with 25 m M GSH (long dash) or GSSG (short dash) (B) Variation (%) of the fluorescence intensity at 520 nmfor DNA-bound S23906-1 in the presence of increasing concentrations of GSH (d) or GSSG (h) The fluorescence of the drug–DNA complexes in the controls (without GSH or GSSG) was considered to be 100%.
Fig 5 Competitive binding of S23906-1 to DNA and SH-containing
molecule The drug (50 l M ) was incubated with or without glutathione
(GSH) or its derivatives (400 l M each) for 1 h at 37 C prior to the
addition of the 117-bp radiolabeled DNA fragment for a further 2 h of
incubation at 37 C The drug free (f) and bound (b) DNA form s were
separated by PAGE on a 6% nondenaturing gel.
Trang 7buffer required for the MS analysis The mass spectra
recorded at 0 and 5 min correspond to a freshly made
solution of S28053-1 The intact drug is, of course,
predominantly found (MH+¼ 562), but a tiny amount of
the diol (MH+¼ 406) and the mono-ester species
(MH+¼ 520 for the C2 hemisuccinate ester and
MH+¼ 448 for the C1 acetate ester) can be detected With
time, the proportions of the diol species gradually increase
and, after 20 h, the diester compound S28053-1 is almost
undetectable For the two monoester species, the one bearing
the acetate group is always present in a smaller amount
compared to that harboring the hemisuccinate ester
func-tion It should be noted that different peaks with a mass of
+14 (peaks at 406 + 14, 448 + 14 or 520 + 14, marked
with different symbols in the Fig 7) are detected and
correspond to the reaction of the drug with methanol used to
wash the needle of the quadrupole just prior to the injection
The asymmetric compound, S28053-1, was then
incuba-ted with GSH overnight at roomtemperature in 1-m
ammonium acetate buffer, pH 7.15, and the resulting mixture was analyzed by MS A typical mass spectrum is presented in Fig 8A and the main peaks have been attributed to the different species obtained In addition to the unreacted compounds (GSH at MH+¼ 308.2 and S28053-1 at MH+¼ 562) and the above mentioned hydrolysis products at MH+¼ 406 (diol) and
MH+¼ 520 (mono hemisuccinate ester), different species corresponding to the GSH reaction products were detected The main peak, at MH+¼ 695.3, corresponds to the expected mass for the adduct between GSH and the drug in its alcohol form, i.e without the ester group on the C2 position By analogy with findings for DNA, we know that this adduct arises fromthe reaction of the monoester compound with GSH A trans-esterification process con-verts the C2 ester into a C1 ester, which then immediately reacts with GSH to formthe expected C2-OH adduct
Fig 7 EI-MS analysis of the hydrolysis of S28053 A 250-l M drug
solution prepared in 1 m M ammonium acetate, pH 7.15, was analyzed
at the indicated incubation time (from 0 to 20 h in panels A–H).
S28053 (MH+¼ 562) hydrolyzes in the mono-hemisuccinate form ()
(MH +
¼ 520), in the mono-acetate form (s) (MH +
¼ 448), and in the diol form(h) (MH +
¼ 406) Three other peaks correspond to the reactivity of methanol (M ¼ 32) (used to wash the needle of the
quadrupole) towards the mono-hemisuccinate form (MH +
¼ 534, r), the mono-acetate form (MH +
¼ 448, ) and the diol form (MH+¼ 406, e), giving the M +14 species.
Fig 8 Alkylation reaction of S28053 with glutathione (GSH) (A) EI-MS analysis of the alkylation reaction of S28053 with GSH A solution containing 100 l M of the drug was incubated with 100 l M
GSH for 16 h at roomtem perature in 1 m M ammonium acetate,
pH 7.15, prior to EI-MS analysis in positive ion mode The structures
of the main species identified are indicated (B) Reaction scheme for the hydrolysis of S28053 and its reaction with GSH The different species indicated, with the corresponding mass, are seen in the EI-MS spectra
of Fig 7 and/or Fig 8A.
Trang 8(Fig 8B) The trans-esterification pathway has been clearly
demonstrated by NMR with the related mono-acetate
compound [12] This C2-OH adduct cannot derive from the
diol compound, which is totally inert towards DNA [11], or
with GSH (data not shown) The peak corresponding to a
mass of MH+¼ 809.5 represents the GSH-bound
C2-hemisuccinate ester adduct, as depicted in the reaction
scheme in Fig 8B Some of the smaller peaks in the mass
spectrumshown in Fig 8A remain to be attributed Some
may correspond to side reaction products after the
trans-esterification process For example, the peak at
MH+¼ 737.4 corresponds to the expected mass for the
GSH-bound C2-acetate adduct
The reaction scheme presented in Fig 8B summarizes the
MS data and illustrates the hydrolysis and GSH reaction
pathways for the compound S28053-1 The reactive site on
the benzoacronycine derivative is the C1 position bearing
the leaving acetate group This group is absolutely essential
Its replacement with a nonleaving group (e.g a methoxy
substituent) totally prevents the reaction with the
electro-philic species, be it GSH or DNA [12]
Cellular studies
The reaction of S23906-1 with GSH may modulate the
cellular response to the benzoacronycine derivative by
quenching the alkylation of DNA, thereby decreasing the
formation of potentially lethal DNA–drug covalent
adducts To test this hypothesis, we investigated the effect
of GSH on drug-induced cytotoxicity using the KB-3-1
epidermoid carcinoma cell line The cells were incubated
with graded concentrations of S23906-1 for 72 h in the
presence or absence of GSH, and the cytotoxic effect was
measured using a conventional colorimetric assay In these
experiments, a solution containing the test drug and GSH
was prepared and then added rapidly to the cellular
medium In the presence of the GSH, the cytotoxic effect
was slightly reduced, by a factor of about three The 50%
inhibitory concentration (IC50) value of 2.2 lM measured
with S23906-1 alone was increased to 7.1 lMin the presence
of 1-mM GSH For comparison, in parallel experiments
performed with the conventional N7-DNA alkylator,
mechlorethamine hydrochloride, we observed a reduction
of cytotoxicity by a factor of about six In this case, the IC50
value of 4.2 lM determined with mechlorethamine alone
increased to 24.8 lM in the presence of mechlorethamine
and 1 mM GSH The tripeptide exerts a mildly negative
effect on the cytotoxicity of the benzoacronycine derivative,
S23906-1
If a significant proportion of the drug reacts with GSH,
there should be less active drug available to alkylate the
genomic DNA in cells The amount of drug–DNA covalent
complexes in cells can be estimated by fluorescence
meas-urements, taking advantage of the specific fluorescence of
the benzoacronycine chromophore To evaluate the effect of
GSH on the formation of DNA adducts in whole cells,
KB-3-1 cells were treated with 10 lM S23906-1 for 1 h in the
presence or absence of GSH or its derivatives The genomic
DNA was subsequently isolated by phenol extraction and
precipitated prior to measurement of the drug–DNA
adducts by fluorescence As shown in Fig 9, the
fluores-cence spectra of a DNA solution obtained fromthe KB-3-1
cells treated with S23906-1 reveal the presence of drug molecules attached to the genomic DNA In the presence of GSH, the level of drug–DNA adducts decreased signifi-cantly, whereas it remained unchanged in the presence of GSSG Again, an effect was observed with the SH-containing analogs, but not with the S-blocked GSH derivatives For example, a marked decrease of the fluor-escence intensity at 500 nmwas detected when cells were treated with a combination of S23906-1 and Cys On the contrary, the association S23906-1 + c-Glu-Gly gave a level of drug–DNA adducts similar to that obtained with the drug alone The reduced cytotoxic activity of S23906-1
in the presence of GSH can thus be explained by a decreased capacity to alkylate DNA Indirectly, these experiments support the idea that the formation of drug–DNA covalent complexes is responsible for the cytotoxic action [12] Finally, we evaluated the effect of BSO on the formation
of drug–DNA covalent complexes in cells BSO decreases GSH synthesis by specifically inhibiting c-glutamylcysteine synthetase [16], the rate-limiting step in GSH biosynthesis BSO is commonly used to deplete cells in GSH, thereby potentiating the cytotoxic action of GSH-reactive anti-cancer drugs, such as melphalan and camptothecin [17] The depleting effect of BSO in KB-3-1 cells was visualized by fluorescence using the fluorescent thiol reagent,
ThioGlo-1TM This maleimide derivative produces a highly fluorescent product upon its reaction with thiol groups, therefore providing a simple and sensitive assay for estimating the GSH content in cell homogenates [18] The decrease of the fluorescence peak centered at 510 nm, observed upon adding increasing concentrations of BSO to the KB-3-1 cells, reflects the GSH-depleting effect (Fig 10A) The cells were first incubated with BSO for 24 h prior to adding 10-lMS23906-1 and, after a further 1 h of incubation, the DNA was extracted and the level of drug–DNA adducts formed in situ was estimated by fluorescence The fluores-cence spectra presented in Fig 10B reveal that the number
of drug–DNA complexes increases with increasing concen-trations of BSO Depleting the cells with BSO reduces the intracellular concentration of GSH and, consequently,
Fig 9 Inhibition of the formation of S23906-1–DNA covalent com-plexes in cells in the presence of glutathione (GSH) or its derivatives Fluorescence-emission spectra of DNA extracted from KB-3-1 epi-dermoid cells treated for 1 h with 10 l M S23906-1 or in the presence of 1-m M GSH, glutathione disulfide (GSSG), L -cysteine (Cys),
N-acetyl-L -cysteine (N-Ac-Cys), glutathione reduced ethyl ester (GSH-O-Et), S-methyl-glutathione (GS-Me) or gamma-glutamic acid-glycine (c-Glu-Gly) The excitation wavelength was set at 300 nmand the emission range from 420 to 650 nm.
Trang 9permits a more pronounced alkylation of DNA The
capacity of the drug to react with the genomic DNA is
inversely proportional to the concentration of GSH The
higher the GSH level, the lower the amount of drug–DNA
adduct and vice versa The increased cytotoxic effect
observed in the presence of 1-m BSO is weak (about
twofold) but consistent (Fig 10C) Altogether, these experi-ments demonstrate that GSH reduces the cytotoxic action
of S23906-1 by decreasing the formation of lethal DNA– drug covalent adducts
Discussion
The compound S23906-1, a diester derivative of 1,2-dihydrobenzo[b]acronycine, has been recently identified as
a highly potent and promising antitumor agent [10] The pharmacological profile of this drug is unusual in the sense that it is markedly active in orthotopic models of human solid tumors, even by the oral route, but only moderately active against murine transplantable tumors [9] It is now well established that DNA is a potential target for this compound We have recently demonstrated that the drug alkylates the N2 position of guanine residues exposed in the minor groove of double helical DNA [11] Moreover, a very recent structure–activity study strongly suggests that the formation of DNA–S23906-1 covalent complexes is respon-sible for the cytotoxic action [12] Nevertheless, the antitumor activity of a given drug rarely (and probably never) relies on the interaction with a single molecular target The possible implication of other targets in the cytotoxic action of S23906-1 must be kept in mind The relative intracellular abundance of GSH (0.5–
10 mM) and the nucleophilicity of its thiolate ion prompted
us to investigate its reactivity with S23906-1 The possibility that bonding of the drug to GSH decreases the extent of DNA adducts and/or other cellular nucleophiles, allowed us confirmthat alkylation is the principal mechanismof action
of S23906-1 The variety of experimental data reported in the present study, summarized in Table 1, fully demon-strates that the hypothesis was correct: S23906-1 does bind covalently to GSH The complex formation requires the SH group of the Cys residue of the tripeptide The drug reacts neither with GSSG nor with other S-blocked derivatives such as GS-NO, GS-DCE or GS-SA A free SH group is required but it is not sufficient because not all SH-containing compounds react covalently with S23906-1 For example, additional MS analyses (not presented here) indicated that the drug does not bind covalently to dithiothreitol or the SH protein, thioredoxin The cysteine
SH group of GSH is necessary, but not sufficient, for covalent complex formation The use of the model dipep-tides suggests that the drug preferentially recognizes the Cys-Gly m oiety of GSH
The experiments performed with the human KB-3-1 carcinoma cell line indicate that GSH modulates the cellular response to S23906-1 by inhibiting DNA alkyla-tion, thereby decreasing the formation of potentially lethal DNA adducts At first sight, this observation may have important biological implications because in vivo the drug will encounter large quantities of GSH and other thiol-containing substrates before it can reach the nucleus of tumor cells However, despite this reactivity towards thiols, S23906-1 presents very high antitumor activities and even shows curative effects in vivo in certain tumor models [9,10]
Although covalent binding to GSH is frequently observed with DNA alkylating agents, the type of adducts formed and their biological effects often vary significantly
Fig 10 Effect of buthionine sulfoximine (BSO) on the cytotoxicity of
S23906-1 and the formation of S23906-1–DNA covalent complexes in
cells (A) Effect of BSO on intracellular glutathione (GSH) contents.
KB-3-1 cells were treated without (plain line) or with 0., 0.25-, 0.5-,
1-or 10-m M BSO (dashed lanes) for 24 h at 37 C prior to lysis, and the
intracellular glutathione (GSH) contents were quantified using
the ThioGlo-1TMreagent The excitation wavelength was 360 nm The
fluorescence intensity was expressed as a percentage of the control
value (plain lane) (B) Fluorescence emission spectra of DNA extracted
fromKB-3-1 cells treated or untreated with increasing concentrations
of BSO (0.1, 0.25, 0.5, 1 or 10 m M ) (dashed lines) for 24 h prior to the
addition of 10 l M S23906-1 for 1 h (plain line) The excitation
wave-length was set at 300 nm The fluorescence intensity was expressed as a
percentage of the control value (C) Growth-inhibition curves for (j)
S23906-1 alone and (n) S23906-1 in the presence of 1-m M BSO
KB-3-1 cells were treated for 72 h with S23906-KB-3-1 prior to measuring the
viability using a conventional tetrazolium-based assay.
Trang 10fromone drug to another The drugs can be classified
into two categories, depending on the positive or negative
contribution of the GSH–drug adducts to the DNA
reactivity The first group of antitumor agents activated
by reaction with GSH includes, for example, the natural
product leinamycin which reacts with thiols to generate an
electrophilic episulfoniumion then reacting with the N7
position of guanines in DNA [19] This group also includes
the promising anticancer drug, irofulven
(6-hydroxymethyl-acylfulvene, also known as MGI 114 or HMAF), which is
thought to alkylate amines in DNA This semisynthetic
derivative of illudin S is currently in phase II
chemothera-peutic clinical trials for a variety of solid tumors [20,21]
Reaction of irofulven with GSH activates a diene
inter-mediate for nucleophilic attack of DNA [22,23] Another
prominent member of this class of thiol-activated antitumor
agents is the distamycin-a-bromoacrylic derivative
PNU-166196, designated brostallicin, which is currently
under-going phase II clinical trials [24] The cytotoxic action of this
DNA minor-groove-binding agent is significantly enhanced
in the presence of GSH and this effect is believed to
originate fromthe formation of GSH–brostallicin covalent
adducts [25] S23906-1 clearly does not belongs to this group
as, in the present case, the GSH–benzoacronycine adducts
reduce the cytotoxic action of the drug It should be
included in the second group of compounds for which the
covalent binding to GSH inactivates the antitumor agent
Similar behaviors have been reported with a variety of
DNA alkylators, especially the nitrogen mustards [26,27],
but these drugs have no real, inherent, affinity for DNA and
thus over-expression of GSH leads to competition between
concentrations of nucleophiles In the case of S23906-1, the
affinity for DNA probably pulls the competition between
the DNA nucleophile and GSH towards the former This
may explain the continuing biological activity and
DNA-alkylation ability of the agent, even in the presence of high
levels of GSH Covalent binding to GSH has also been
observed with the drug mitomycin C (MC) [28,29] The
formation of GSH–MC conjugates competes with DNA
alkylation, as is the case with S23906-1 Ternary GSH–MC–
guanine N2 DNA adducts have been isolated and
charac-terized [30] The antitumor drug, cisplatinum, also reacts
covalently with GSH and cysteine [31,32], as well as the
pyrrolobenzodiazepine dimers, which form interstrand
covalent DNA crosslinks and similarly alkylate guanines
at their N2 positions in the duplex minor groove Their
cytotoxicity is also modulated by GSH and other
nonpro-tein thiols, where reversible adducts are formed [33,34]
The formation of covalent adducts between S23906-1 and
GSH can be viewed as a detoxification system Considering
that the intracellular concentration of S23906-1 in the
tumors is probably very low, whereas the intracellular
concentration of GSH is relatively high (generally >1 mM),
one can assume that the formation of GS–benzoacronycine
adducts will be favored and that these adducts can be
eliminated by different transporters, such as the
multidrug-resistance-associated protein (MRP) which functions as a
GSH S-conjugate carrier in leukemia and in lung carcinoma
cells [35–37] However, the fate of the GS-S23906-1 adducts
are as yet unknown and at this stage we cannot eliminate the
possibility that these glutathionyl conjugates remain capable
of alkylating macromolecules and thus serve as a transport
formand a reservoir for the drug For example, the monoGSH-conjugate of cyclophophasmide can reform the tumor active metabolite 4-hydroxy-cyclophophasmide [38] Although the GSH-S23906-1 adducts are apparently very stable and probably eliminated as such, we cannot reject the possibility that in a specific cell/tissue environment, the conjugates hydrolyze to generate a potentially alkylating drug species More work on the fate and distribution of the GSH-conjugates of the benzoacronycine is required More information is also needed on the reactivity of the drug towards GSH S-transferases which often participate in the development of drug resistance The role of GSH-dependent DNA repair should also be investigated to better compre-hend the mechanism of action of S23906-1 There is also the possibility that the GSH–S23906-1 adducts detected here using an in vitro system, either do not formor formonly very weakly in vivo For example, the formation of cisplatin– glutathione adducts was found in vitro, but not in vivo after concomitant administration of cisplatin and glutathione to rats and cancer patients [39]
The primary objective of the present study was to investigate further the reactivity of S23906-1 towards the bionucleophiles DNA and GSH The covalent binding of the drug to GSH reduced the formation of DNA adducts and slightly decreased the cytotoxic potential of the molecule There is now little room for doubt that DNA is
an important target of S23906-1 and the reaction mechan-ismclearly implicates the C1 functionality The present study, demonstrating the formation of covalent adducts between GSH and the antitumor drug S23906-1, sets several directions for further works to enhance our understanding
of the mechanism of action of this promising anticancer agent
Acknowledgements
The authors thanks Dr John A Hickman (Head of the Cancer Research Division, Institut de Recherches Servier) for stimulating discussions and useful comments on the manuscript and Dr B Serkis (Division of Physicochemistry, Institut de Recherches Servier) for the separation of the two cis enantiomers of S23906-1 This work was carried out under the support of a Servier research grant to C B and a fellowship to M.-H D.-C fromthe Association pour la Recherche sur
le Cancer.
References
1 Hughes, G.K., Lahey, F.N., Price, J.R & Webb, L.J (1948) Alkaloids of the Australian rutaceae Nature 162, 223–224.
2 Svoboda, G., Poore, G.A., Simpson, P.J & Boder, G.B (1966) Alkaloids of Acronychia Baueri Schott I Isolation of the alkaloids and a study of the antitumor and other biological properties of acronycine J Pharm Sci 55, 759–768.
3 Gout, P.W., Dunn, B.P & Beer, C.T (1971) Effects of acronycine
on nucleic acid synthesis and population growth in mammalian tumor cell cultures J Cell Physiol 78, 127–138.
4 Dunn, B.P., Gout, P.W & Beer, C.T (1973) Effects of the anti-neoplastic alkaloid acronycine on nucleoside uptake and incor-poration into nucleic acids by cultured L5178Y cells Cancer Res.
33, 2310–2319.
5 Dorr, R.T., Liddil, J.D., Von Hoff, D.D., Soble, M & Osborne, C.K (1989) Antitumor activity and murine pharmacokinetics of parenteral acronycine Cancer Res 49, 340–344.